Market Overview

Bernstein Says Generic Copaxone Win Could Help Momenta Break through $20 Level

Related MNTA
Benzinga's Top Upgrades, Downgrades For February 22, 2017
15 Biggest Mid-Day Losers For Tuesday
Momenta Delay Means Race For Copaxone Generic Is On (Seeking Alpha)
Related TEVA
The Market In 5 Minutes
Risks For Teva Remain As CEO Search Continues
Court affirms Pernix's Zohydro ER patents; shares ahead 35% premarket (Seeking Alpha)

Momenta Pharmaceuticals (NASDAQ: MNTA) shares spiked sharply Friday following news of a legal ruling invalidating Teva Pharmaceutical's (NYSE: TEVA) patents on Copaxone in 2015 and partly invalidating its 2014 patents.

Bernstein analyst Ronny Gal sees a 75 percent chance of the court decision being favorable for Momenta. The ruling could open the door to Momenta introducing a generic Copaxone within the next few months, according to Gal.

If Momenta is able to introduce the first generic Copaxone by May 2014, Gal believes shares could be valued at $30. This is nearly twice the $15.35 level shares were trading at prior to Friday's spike.

Gal believes a later release by Q4 2015 could spell upside of 30 percent from current levels to $23 per share.

Gal rates Momenta at Outperform with a $20 price target.

Latest Ratings for MNTA

Feb 2017Leerink SwannDowngradesOutperformMarket Perform
Nov 2016Aegis CapitalInitiates Coverage OnHold
Oct 2016BarclaysUpgradesEqual-WeightOverweight

View More Analyst Ratings for MNTA
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Legal Analyst Ratings Movers


Related Articles (MNTA + TEVA)

View Comments and Join the Discussion!